The third monoclonal antibody directed to surface receptors discovered in order of time is Cetuximab (Erbitux®) directed against the epidermal growth factor receptor (EGFR), frequently altered in numerous tumors, especially colorectal carcinomas, NSCLC and head and neck cancers (Vokes and Chu, 2006). This evidence concerns the gene EGFR and colorectal carcinoma.